Karen Page

Background

Karen Page is a General Partner and Board Partner at B Capital Group, the global multi-stage venture and growth equity firm co-founded by Eduardo Saverin and Raj Ganguly ¹. She is based in San Francisco ¹.

Page earned a BS from Towson University and an MS in Advanced Behavioral Science and Organizational Development from Johns Hopkins Carey Business School, where she serves on the executive committee of the Carey Business School Dean’s Advisory Council ².

Before joining B Capital, Page built her career across two marquee Silicon Valley companies. At Box, she was the seventh employee and a founding executive, spending nearly a decade focused entirely on go-to-market strategy — building out partnerships and business development, cultivating C-level relationships, founding Box.org (the company’s nonprofit program), and leading the Industry Verticals team ³⁴. She played a central role in growing Box from zero revenue to over $1 billion in valuation before its 2015 IPO ¹.

After Box, she joined Apple, where she led the Enterprise GTM team — overseeing commercial channel operations, strategic partnerships worth approximately $4 billion with firms including Deloitte, SAP, and IBM, the Mobility Partner Program, and Apple’s Industry team ³⁴.

Page joined B Capital Group in February 2019 as the firm’s seventh partner ⁵. She initially joined as a growth-stage investor writing checks for Series B, C, and D companies. Approximately 18 months into her tenure, she helped launch B Capital’s early-stage investment effort alongside Howard Morgan and Gabe Greenbaum, adding coverage at pre-seed, seed, and Series A ³.

Page is a member of Class 27 of the Kauffman Fellows Program and a former trustee at the Computer History Museum and The Newseum ².

Stated Thesis

Page publicly describes her investment focus as enterprise go-to-market companies solving hard problems in large markets, with particular interest in healthcare technology, fintech, and cybersecurity. She frames herself as “a generalist moving toward specialization,” anchoring her thesis around her deep operational background at Box and Apple ³.

She emphasizes three core diligence questions: who is the target audience, what is the business model, and what gives founders an unfair advantage ³. On go-to-market, she stresses understanding customer buying cycles, establishing product-market fit through meaningful customer engagement, and building distribution infrastructure before scaling sales ⁶.

B Capital’s website describes her focus as investing across seed to growth in Information Technology, FinTech/Financial Services, Healthcare, and B2B/Enterprise Software ¹.

Inferred Thesis

Based on 13 verified investments where Page had a direct investment or board role at B Capital (2019–2024). Sample size supports directional analysis but not precise sector percentages.

Sector distribution (13 verified investments): - Healthcare / digital health: Bright.md (2020, Series C), Centivo (2020, Series B), UpLift (2023), Isaac Health (2024, Seed) — 4 of 13 investments (31%) - Enterprise SaaS / revenue operations: Clari (2021, Series E), Pendo (2021, Series F), Highspot (2022, Series F), Satori Cyber (2021, Series A) — 4 of 13 (31%) - Fintech / payments: Plastiq (2020, Series D), Percent (board observer) — 2 of 13 (15%) - Supply chain / operations: Anvyl (2022, Series B) — 1 of 13 (8%) - Climate tech / infrastructure: Overstory (2022 seed extension; 2023, Series A) — 1 investment (8%) - Workforce management: Deputy (board member 2018–2023) — 1 of 13 (8%)

Stage distribution: Page explicitly describes her evolution from growth-only investor (Series B–D at entry in 2019) to a multi-stage investor covering pre-seed through growth ³. Her verified investments span seed (Isaac Health, Overstory seed extension) through large growth rounds (Pendo Series F at $150M, Highspot Series F at $248M). The bulk of disclosed deals fall in Series B–C range, consistent with B Capital’s historical positioning.

Sector patterns vs. stated thesis: Page’s actual portfolio confirms her stated emphasis on enterprise B2B software and healthcare technology. These two verticals together account for approximately 62% of her verified investments. The fintech exposure (Plastiq, Percent) is consistent with B Capital’s stated fintech focus but lower than the enterprise/health proportion. The Overstory investment represents a distinct climate-tech thesis that is newer (2022–2023) and not prominently featured in early public statements.

Founder profile preferences: Page’s investments consistently feature experienced domain operators-turned-founders (Centivo founders from healthcare payer industry; Bright.md founders with clinical and telehealth backgrounds; Plastiq founders with fintech operations background; Anvyl with supply chain industry veterans). This pattern aligns with her stated emphasis on founders with an “unfair advantage” in their domain ³.

Geographic concentration: All verified investments are U.S.-domiciled companies, consistent with Page’s San Francisco base and focus on North American enterprise markets. This contrasts with some B Capital colleagues who invest heavily in South/Southeast Asia.

Go-to-market operationalization as differentiator: A distinctive pattern in Page’s investments is that nearly all portfolio companies serve enterprise buyers and rely on complex B2B sales motions — the precise area where Page’s Box and Apple experience is most directly applicable. She has described providing direct GTM support to portfolio companies as a core value-add ³.

Co-investor patterns: Page’s investments show frequent co-investment with Bain Capital Ventures (Centivo Series B), Seven Peaks Ventures (Bright.md), Silver Lake (Clari Series E, Pendo Series F), AlleyCorp and First Round Capital (Anvyl), Evolution Equity Partners (Satori Series A), and The Nature Conservancy (Overstory Series A).

Portfolio

Note: This table represents a portion of Karen Page’s investments at B Capital. Angel investments made prior to joining B Capital (AllStripe, The Riveter, Mutiny, HarperWilde, Glamsquad, EverLoved) are not included as they predate her institutional role ². Deputy board membership began before her formal B Capital start date; the investment vehicle is not confirmed as B Capital. Plastiq filed for Chapter 11 bankruptcy in May 2023 after the funding period.

In Their Own Words

On her go-to-market background and Box: “My whole entire responsibility while I was there for almost a decade was to help Box get on the map, make us look bigger than we were.” ³

On career evolution to investing: “Joined as a growth team investor…now I’m writing checks at the preseed, seed, and A stage.” ³

On what she looks for in founders: “Who is their target audience? What is their business model? What gives founders an unfair advantage?” ³

On the enterprise sales hiring challenge: “It’s probably one of the most complex periods of time for a lot of companies…the ability of a founder to both hold on and let go during that process is really a testament to the leadership abilities.” ³

On product-led growth: “I don’t think you can decide to be a product-led growth company. I think it’s something that you can strive for.” ⁶

On team empowerment: “The ability of a leader to empower their teams for success comes back in ways that are just immeasurable.” ⁶

On the Plastiq investment (2020): “SMBs represent the largest business segment in our country but are chronically underserved when it comes to working capital. They drive almost half of economic activity and create nearly two-thirds of new jobs, yet SMBs can’t get access to the capital they need. Plastiq’s impressive growth shows they are filling a critical gap by bridging credit access and payables, and B Capital believes the company is positioned to become the leading working capital solution for small businesses.” ⁸

On the Centivo investment (2020): “The rising cost of healthcare continues to be a challenge for both employers and their employees. Centivo is structurally lowering the cost of healthcare purchasing by using technology and analytics to create efficiencies and improve outcomes. Their solution yields sustainable savings and boosts quality for the long term for employers and employees alike.” ¹⁰

On the Bright.md investment (2020): “The Bright.md team continues to find new ways to help its health system partners provide highly responsive care. When coronavirus struck in January, Bright.md responded immediately with a new, free, comprehensive COVID-19 screening tool based on Centers for Disease Control and Prevention (CDC) guidelines. The company’s keen, nimble ability to adapt to the needs of health systems has helped them deliver an excellent patient experience and increased provider efficiency. That truly sets Bright.md apart from anything else in the market.” ⁹

On the Anvyl investment (2022): “Anvyl’s success in capitalizing on the $20+ billion supply chain software industry reflects brands’ increasing understanding of how critical it is to have visibility into, predict, and act on positive – and adverse – supply chain events in unprecedented ways. I was excited to work with Anvyl given the lack of software from order to delivery of inbound goods. Anvyl’s world class team and product have taken on one of the oldest and largest industries that has not yet adopted technology with an intense focus on providing the most intelligent supply chain software in the world.” ¹⁵

On the Overstory investment (2023): “Utility companies now have an acute problem with the confluence of catastrophic wildfires, extreme weather, power outages and a changing climate. This has forced these providers to adjust the way they work and ultimately take a more data-driven approach. We are proud to partner with the incredible team at Overstory and support their work to leverage AI and create a safer, more reliable grid.” ¹⁷

On the Isaac Health investment (2024): “We are currently at a historic inflection point for brain health with the first full FDA-approved disease modifying treatment for early-stage Alzheimer’s disease, and the company’s commitment to innovation, coupled with the vast potential size of the brain health market, strongly aligns with our vision for the future of healthcare. We look forward to collaborating with Isaac Health as they continue to make significant strides in transforming patient care.” ¹⁹

What Founders Say

Ray Costantini, co-founder and CEO of Bright.md, on B Capital’s continued support: “Our investors, including Seven Peaks Ventures and B Capital, continue to emphatically support our purpose of making healthy happen faster by increasing clinical capacity through our technology.” ⁹

No additional independently sourced testimonials specifically about Karen Page’s value as an individual investor were found during research. Firm website testimonials are not available for B Capital at this time.

Sources